In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma

• Montserrat Pérez-Salvia,
• Eneko Aldaba,
• Yosu Vara,
• Myriam Fabre,
• Cristina Ferrer,
• Carme Masdeu,
• Aizpea Zubia,
• Eider San Sebastian,
• Dorleta Otaegui,
• Pere Llinàs-Arias,
• Margalida Rosselló-Tortella,
• Maria Berdasco,
• Catia Moutinho,
• Fernando Setien,
• Alberto Villanueva,
• Eva González-Barca,
• Josep Muncunill,
• José-Tomás Navarro,
• Miguel A. Piris,
• Fernando P. Cossio,
• Manel Esteller

Affiliations

Montserrat Pérez-Salvia

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet, Barcelona, Catalonia

Eneko Aldaba

Quimatryx, San Sebastian

Yosu Vara

Quimatryx, San Sebastian

Myriam Fabre

Oncomatryx, Arteaga Auzoa, 43, Derio

Cristina Ferrer

Oncomatryx, Arteaga Auzoa, 43, Derio

Carme Masdeu

Department of Organic Chemistry I, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), San Sebastián

Aizpea Zubia

Department of Organic Chemistry I, Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Donostia International Physics Center (DIPC), San Sebastián

Eider San Sebastian

Department of Organic Chemistry I, Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Donostia International Physics Center (DIPC), San Sebastián

Dorleta Otaegui

Mass Spectrometry Platform, CIC biomaGUNE, San Sebastian

Pere Llinàs-Arias

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet, Barcelona, Catalonia

Margalida Rosselló-Tortella

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet, Barcelona, Catalonia

Maria Berdasco

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet, Barcelona, Catalonia

Catia Moutinho

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet, Barcelona, Catalonia

Fernando Setien

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet, Barcelona, Catalonia

Alberto Villanueva

Laboratory of Translational Research, Catalan Institute of Oncology (ICO), IDIBELL L’Hospitalet, Barcelona, Catalonia

Eva González-Barca

Department of Hematology, ICO-Hospital Duran i Reynals, IDIBELL, University of Barcelona, L’Hospitalet, Barcelona, Catalonia

Josep Muncunill

Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Catalonia

José-Tomás Navarro

Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Catalonia

Miguel A. Piris

Pathology Service, Fundación Jiménez Díaz, Madrid

Fernando P. Cossio

Department of Organic Chemistry I, Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Donostia International Physics Center (DIPC), San Sebastián

Manel Esteller

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) L’Hospitalet, Barcelona, Catalonia;Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid;Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), L’Hospitalet, Catalonia;Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain